Email updates

Keep up to date with the latest news and content from BMC Immunology and BioMed Central.

Open Access Highly Accessed Research article

Differential effects of Paclitaxel on dendritic cell function

Justin John1, Mohammed Ismail2, Catherine Riley2, Jonathan Askham3, Richard Morgan2, Alan Melcher3 and Hardev Pandha2*

Author Affiliations

1 Systems Biology Laboratory (UK) Ltd. Milton Park, Abingdon, Oxon, OX14 4SA, UK

2 Oncology, Postgraduate Medical School, Daphne Jackson Road, University of Surrey, Guildford, GU2 7WG, UK

3 Academic Unit of Oncology and the Cancer Research UK Clinical Centre, St James's University Hospital, Leeds, LS12 6AG, UK

For all author emails, please log on.

BMC Immunology 2010, 11:14  doi:10.1186/1471-2172-11-14

Published: 19 March 2010



The potential utility of dendritic cells (DC) as cancer vaccines has been established in early trials in human cancers. The concomitant administration of cytotoxic agents and DC vaccines has been previously avoided due to potential immune suppression by chemotherapeutics. Recent studies show that common chemotherapy agents positively influence adaptive and innate anti-tumour immune responses.


We investigated the effects of paclitaxel on human DC biology in vitro. DCs appear to sustain a significant level of resistance to paclitaxel and maintain normal viability at concentrations of up to 100 μmol. In some cases this resistance against paclitaxel is significantly better than the level seen in tumour cell lines. Paclitaxel exposure led to a dose dependent increase in HLA class II expression equivalent to exposure to lipopolysaccharide (LPS), and a corresponding increase in proliferation of allogeneic T cells at the clinically relevant doses of paclitaxel. Increase in HLA-Class II expression induced by paclitaxel was not blocked by anti TLR-4 antibody. However, paclitaxel exposure reduced the endocytic capacity of DC but reduced the expression of key pro-inflammatory cytokines such as IL-12 and TNFα. Key morphological changes occurred when immature DC were cultured with 100 μmol paclitaxel. They became small rounded cells with stable microtubules, whereas there were little effects on LPS-matured DC.


The effect of paclitaxel on human monocyte derived DC is complex, but in the clinical context of patients receiving preloaded and matured DC vaccines, its immunostimulatory potential and resistance to direct cytotoxicity by paclitaxel would indicate potential advantages to co-administration with vaccines.